ElSayed et al. reported that rhPRG4 treatment activates PP2A, and reduces MSU crystal phagocytosis, caspase-1 activity, and IL-1β production in human macrophages, gout, and normal human peripheral blood mononuclear cells (PBMCs), while okadaic acid, a PP2A inhibitor, reverses rhPRG4’s effect [117]. This evidence concerns the gene PTPA and gout.